Evidence map›Paper›PMID 28384179›Full record

ArticlePloS one2017

An intravaginal ring for real-time evaluation of adherence to therapy.

John A Moss, Marc M Baum, Jeremiah T Easley, Darren M Cox, Thomas J Smith

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

John A MossDepartment of Chemistry, Oak Crest Institute of Science, Monrovia, California, United States of America.ORCID http://orcid.org/0000-0001-8091-3245
Marc M BaumDepartment of Chemistry, Oak Crest Institute of Science, Monrovia, California, United States of America.
Jeremiah T EasleyPreclinical Surgical Research Laboratory, Colorado State University, Fort Collins, Colorado, United States of America.
Darren M CoxDepartment of Chemistry, Oak Crest Institute of Science, Monrovia, California, United States of America.
Thomas J SmithAuritec Pharmaceuticals, Inc., Pasadena, California, United States of America.
Oak Crest Institute of Science · USAuritec Pharmaceuticals (United States) · USColorado State University · US

Funding

An intravaginal ring for real-time evaluation of adherence to topical vaginaR41AI104549 · NIAID · AURITEC PHARMACEUTICALS, INC. · PI MOSS, JOHN A, SMITH, THOMAS J. · 2013 to 2013
$212k
NIAID NIH HHS R41 AI104549
6 · The paper itself

Abstract

Two recent Phase III clinical trials to investigate an intravaginal ring for preventing HIV infection demonstrated that adherence to prescribed device use was a primary driver of efficacy. Surrogate methods for determining adherence in the studies were limited in their inability to monitor temporal patterns of use and allow deconvolution of the effects of adherence and device efficacy on HIV infection rates. To address this issue, we have developed functionality in an intravaginal ring to continuously monitor when the device is being used and maintain a log of adherence that can be accessed by clinicians after it is removed. An electronic module fabricated with common, inexpensive electronic components was encapsulated in a silicone intravaginal ring. The device uses temperature as a surrogate measure of periods of device insertion and removal, and stores a record of the data for subsequent retrieval. The adherence-monitoring intravaginal ring accurately recorded the device status over 33 simulated IN-OUT cycles and more than 1000 measurement cycles in vitro. Following initial in vitro testing in a temperature-controlled chamber, the device was evaluated in vivo in sheep using a predetermined insertion/removal pattern to simulate intravaginal ring use. After insertion into the vaginal cavity of a sheep, the logged data correctly indicated the device status over 29 hours of continuous measurement including three cycles of insertion and removal. The device described here is a promising, low-cost method for real-time adherence assessment in clinical trials involving medicated intravaginal rings or other intravaginal devices.

Indexed as

Drug Administration RoutesPatient ComplianceVaginaAnimalsAnti-HIV AgentsFemaleHIV InfectionsHumansPre-Exposure ProphylaxisReverse Transcriptase InhibitorsSheepSoftwareTenofovirAnti-HIV AgentsReverse Transcriptase InhibitorsTenofovir

Identifiers

PMID28384179
PMCPMC5383054
OpenAlexW2604846786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.